Trials / Completed
CompletedNCT00276107
Study Evaluating Prevenar Vaccine in Healthy Infants
An Open-Label Trial of the Immunogenicity and Safety of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine [Diphteria CRM197 Protein Conjugate]) in Healthy Infants at 2, 4 and 6 Months of Age
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 42 Days – 100 Days
- Healthy volunteers
- Accepted
Summary
To determine the immunogenicity of Prevenar in infants immunized at 2, 4 and 6 months of age. To determine the antibody responses to the seven pneumococcal vaccine serotypes one month after second dose and determine the safety of Prevenar in infants immunized at 2,4 and 6 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prevenar |
Timeline
- Start date
- 2004-12-01
- Completion
- 2005-12-01
- First posted
- 2006-01-12
- Last updated
- 2009-07-29
Source: ClinicalTrials.gov record NCT00276107. Inclusion in this directory is not an endorsement.